SEPARATION AND IDENTIFICATION OF FORCED DEGRADATION PRODUCTS OF LOFEXIDINE BY USING LC-MS/MS

MASTANAMMA SK; SATYA ANJALI T; TEJASWI J; CHIRANMAI M; HEMA LATHA K

doi:10.22159/ajpcr.2022.v15i9.45117

Authors

MASTANAMMA SK Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
SATYA ANJALI T Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
TEJASWI J Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
CHIRANMAI M Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.
HEMA LATHA K Department of Pharmaceutical Analysis, University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur, Andhra Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i9.45117

Keywords:

Lofexidine, Degradation products, Stress condition, LC-MS/MS

Abstract

Objectives: A rapid and reliable isocratic LC-MS/MS method was developed and validated for the separation and identification of stress degradation products (DPs) of lofexidine.

Methods: Lofexidine, a non-opioid centrally acting alpha2-adrenergic receptor agonist, was subjected to hydrolysis (acidic, alkaline, and neutral), oxidation, photolysis, and thermal stress as per International Council on Harmonization specified conditions. The drug showed extensive degradation under alkaline, acidic, oxidation, and photolytic stress condition.

Results: A total of 14 DPs were observed and the chromatographic separation of the drug and its DPs were achieved on waters symmetry C18 (150 × 4.6 mm, 3.5 μm) column using water and acetonitrile (75:25 v/v) as mobile phase. The DPs were separated and identified using LC-MS/MS. The LC-MS/MS method was validated with respect to specificity, linearity, accuracy, and precision.

Conclusion: The proposed method was used for impurity profiling and routine quality control tests of lofixidine.

Downloads

Download data is not yet available.

References

Drug Random House. Vol. 1. Unbridge. Available from: https:// dictionary.com [Last accessed on 2007 Sep 20].

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. QlA. Stab Test New Drug Substitute Products. Geneva, Switzerland: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2006. p. R2.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (R1): Validation of Analytical Procedures: Text and Methodology. In: International Conference on Harmonization. Geneva: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2005.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Impurities in New Drug Substances Q3A. In: International Conference on Harmonisation. Vol. R2. Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations; 2006.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Impurities in New Drug Products Q3B. In: International Conference on Harmonisation 2006. Vol. R2. Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations; 2006.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Impurities: Guideline for Residual Solvents Q3C. In: International Conference on Harmonisation. Vol. R6. Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations; 2016.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Impurities: Guideline for Elemental Impurities. International Conference on Harmonisation 2014. Vol. Q3D. Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations; 2004.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q6A, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. Geneva, Switzerland: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; 2006.

Heyden YV, Nijhuis A, Smeyers-Verbeke J, Vandeginste BG, Massart DL Smith; et al. Guidance for robustness/ruggedness tests in method validation. J Pharm Biomed Anal 2001;24:723-53. doi: 10.1016/s0731-7085(00)00529-x, PMID 11248467.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Harmonised tripartite Guideline q2(R1), Current. 4th Version. Parent Guideline. Geneva: Step Publishing; 1994.

Al9Ghananeem AM. Pharmacokinetics of lofexidine hydrochloride in healthy volunteers. J Pharm Sci 2009;98:319-26. doi: 10.1002/ jps.21401, PMID 18393298.

Yu E, Miotto K, Akerele E, O’Brien CP, Ling W, Kleber H, et al. Clinical pharmacokinetics of lofexidine, the α 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J Drug Alcohol Abuse 2009;34:611-6.